NewAmsterdam Pharma (NAMS) Financials

$15.90 -0.52 (-3.17%)

As of 01:52 PM Eastern

Annual Income Statements for NewAmsterdam Pharma

This table shows NewAmsterdam Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-7.02	-32	-30	-177	-242
Consolidated Net Income / (Loss)	-7.02	-32	-23	-177	-242
Net Income / (Loss) Continuing Operations	-7.02	-32	-30	-177	-242
Total Pre-Tax Income	-7.02	-32	-23	-177	-242
Total Operating Income	-6.63	-34	-3.56	-183	-176
Total Gross Profit	0.00	0.01	103	14	46
Total Revenue	0.00	0.01	103	14	46
Operating Revenue	0.00	0.01	103	14	46
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	6.63	34	106	197	222
Selling, General & Admin Expense	1.69	5.44	20	38	70
Research & Development Expense	4.94	28	87	159	151
Total Other Income / (Expense), net	-0.42	1.39	-27	6.06	-65
Interest Expense	0.42	0.24	0.29	0.00	0.00
Interest & Investment Income	0.00	-	0.00	11	17
Other Income / (Expense), net	-	1.63	-27	-5.23	-82
Income Tax Expense	0.00	0.00	0.00	0.03	-0.00
Basic Earnings per Share	($0.76)	-	($1.19)	($2.15)	($2.56)
Weighted Average Basic Shares Outstanding	-	-	81.56M	89.27M	109.82M
Diluted Earnings per Share	($0.76)	($1.37)	($1.19)	($2.15)	($2.56)
Weighted Average Diluted Shares Outstanding	-	-	81.56M	89.27M	109.82M
Weighted Average Basic & Diluted Shares Outstanding	-	-	81.56M	89.27M	109.82M

This table shows NewAmsterdam Pharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-42	-38	-47	-49	-94	-39	-17	-92
Consolidated Net Income / (Loss)	-42	-38	-47	-49	-94	-39	-17	-92
Net Income / (Loss) Continuing Operations	-42	-38	-47	-49	-94	-39	-17	-92
Total Pre-Tax Income	-42	-38	-47	-49	-94	-39	-17	-92
Total Operating Income	-40	-42	-50	-51	-55	-53	-25	-43
Total Gross Profit	8.63	1.72	2.94	0.80	1.40	2.28	29	13
Total Revenue	8.63	1.72	2.94	0.80	1.40	2.28	29	13
Operating Revenue	8.63	1.72	2.94	0.80	1.40	2.28	29	13
Total Operating Expenses	48	44	52	52	57	55	54	56
Selling, General & Admin Expense	8.06	9.86	9.13	11	14	16	18	21
Research & Development Expense	40	34	43	41	42	38	36	35
Total Other Income / (Expense), net	-2.17	4.19	2.43	1.61	-38	14	8.36	-49
Interest & Investment Income	0.94	4.61	3.06	2.67	3.08	4.87	4.44	4.49
Other Income / (Expense), net	-3.11	-0.42	-0.63	-1.06	-41	8.70	3.91	-53
Basic Earnings per Share	($0.51)	($0.47)	($0.57)	($0.60)	($1.06)	($0.41)	($0.18)	($0.91)
Weighted Average Basic Shares Outstanding	-	-	-	89.27M	89.98M	90.02M	92.39M	109.82M
Diluted Earnings per Share	($0.51)	($0.47)	($0.57)	($0.60)	($1.06)	($0.41)	($0.18)	($0.91)
Weighted Average Diluted Shares Outstanding	-	-	-	89.27M	89.98M	90.02M	92.39M	109.82M
Weighted Average Basic & Diluted Shares Outstanding	-	-	-	89.27M	89.98M	90.02M	92.39M	109.82M

This table details how cash moves in and out of NewAmsterdam Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	6.52	50	402	-132	438
Net Cash From Operating Activities	-7.28	-28	11	-141	-159
Net Cash From Continuing Operating Activities	-7.28	-28	11	-141	-159
Net Income / (Loss) Continuing Operations	-7.02	-32	-23	-177	-242
Consolidated Net Income / (Loss)	-7.02	-32	-23	-177	-242
Depreciation Expense	0.00	0.02	0.01	0.05	0.11
Amortization Expense	-	-	0.00	0.00	-0.23
Non-Cash Adjustments To Reconcile Net Income	0.39	-0.45	23	30	116
Changes in Operating Assets and Liabilities, net	-0.65	4.32	10	5.87	-33
Net Cash From Investing Activities	0.00	-0.02	-0.22	-0.02	-63
Net Cash From Continuing Investing Activities	0.00	-0.02	-0.22	-0.02	-63
Purchase of Property, Plant & Equipment	-	-0.02	-0.22	-0.02	-0.67
Purchase of Investments	-	-	0.00	0.00	-62
Net Cash From Financing Activities	14	78	392	8.91	660
Net Cash From Continuing Financing Activities	14	78	392	8.91	660
Repurchase of Common Equity	-	0.00	0.00	0.00	-0.54
Issuance of Common Equity	-	78	397	0.00	0.00
Other Financing Activities, net	-	-	-5.05	8.91	660
Cash Interest Paid	-	-	0.28	0.00	0.00
Cash Income Taxes Paid	-	-	0.00	0.03	0.00

This table details how cash moves in and out of NewAmsterdam Pharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-29	-23	-47	-33	143	-50	-13	357
Net Cash From Operating Activities	-32	-29	-47	-33	-55	-54	-13	-37
Net Cash From Continuing Operating Activities	-32	-29	-47	-33	-55	-54	-13	-37
Net Income / (Loss) Continuing Operations	-42	-38	-47	-49	-94	-39	-17	-92
Consolidated Net Income / (Loss)	-42	-38	-47	-49	-94	-39	-17	-92
Depreciation Expense	0.01	0.01	0.01	0.01	0.02	0.02	0.03	0.05
Non-Cash Adjustments To Reconcile Net Income	9.31	11	2.98	6.08	50	-9.64	3.60	72
Changes in Operating Assets and Liabilities, net	0.83	-2.46	-2.84	10	-11	-5.35	0.52	-17
Net Cash From Investing Activities	-0.01	-0.01	-0.01	-0.00	-0.39	-0.21	-0.08	-62
Net Cash From Continuing Investing Activities	-0.01	-0.01	-0.01	-0.00	-0.39	-0.21	-0.08	-62
Purchase of Property, Plant & Equipment	-0.01	-0.01	-0.01	-0.00	-0.39	-0.21	-0.08	-0.00
Net Cash From Financing Activities	2.39	6.33	0.19	-	198	4.66	0.06	457
Net Cash From Continuing Financing Activities	2.39	6.33	0.19	-	198	4.66	0.06	457
Repurchase of Common Equity	0.00	-	-	-	-0.52	-	-	-0.03
Other Financing Activities, net	2.39	6.33	0.19	-	199	4.66	0.06	457

This table presents NewAmsterdam Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024
Total Assets	68	569	347	865
Total Current Assets	67	479	347	863
Cash & Equivalents	60	469	340	772
Short-Term Investments	-	-	0.00	62
Prepaid Expenses	0.00	0.16	6.34	24
Other Current Assets	-	-	0.00	4.95
Plant, Property, & Equipment, net	0.22	0.15	0.05	0.24
Total Noncurrent Assets	0.81	89	0.26	0.97
Goodwill	-	-	0.17	0.53
Other Noncurrent Operating Assets	-	-	0.09	0.43
Total Liabilities & Shareholders' Equity	68	569	347	865
Total Liabilities	11	50	59	107
Total Current Liabilities	11	38	50	107
Accounts Payable	11	20	28	18
Current Deferred Revenue	0.00	14	8.94	6.01
Other Current Liabilities	0.06	0.07	13	83
Total Noncurrent Liabilities	0.13	12	8.81	0.20
Noncurrent Deferred Revenue	0.00	4.81	1.02	0.00
Other Noncurrent Operating Liabilities	0.00	12	7.79	0.20
Commitments & Contingencies	-	-	0.00	0.00
Total Equity & Noncontrolling Interests	56	518	288	758
Total Preferred & Common Equity	56	518	288	758
Total Common Equity	56	518	288	758
Common Stock	95	641	601	1,312
Retained Earnings	-	-	-317	-559
Accumulated Other Comprehensive Income / (Loss)	-39	-128	4.42	4.47

This table presents NewAmsterdam Pharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024
Total Assets	488	447	439
Total Current Assets	488	445	438
Cash & Equivalents	481	431	423
Prepaid Expenses	6.68	15	15
Plant, Property, & Equipment, net	0.10	0.23	0.23
Total Noncurrent Assets	0.54	1.10	1.09
Goodwill	0.49	0.54	0.59
Other Noncurrent Operating Assets	0.05	0.56	0.49
Total Liabilities & Shareholders' Equity	488	447	439
Total Liabilities	77	59	60
Total Current Liabilities	60	45	41
Accounts Payable	19	15	18
Current Deferred Revenue	8.12	6.06	4.50
Other Current Liabilities	33	24	19
Total Noncurrent Liabilities	17	14	19
Noncurrent Deferred Revenue	0.44	0.22	0.00
Other Noncurrent Operating Liabilities	16	14	19
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	412	387	379
Total Preferred & Common Equity	412	387	379
Total Common Equity	412	387	379
Common Stock	818	833	841
Retained Earnings	-411	-450	-466
Accumulated Other Comprehensive Income / (Loss)	4.42	4.42	4.42

This table displays calculated financial ratios and metrics derived from NewAmsterdam Pharma's official financial filings.

Metric	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-
Revenue Growth	0.00%	0.00%	1,008,087.71%	-86.28%	223.37%
EBITDA Growth	0.00%	-384.22%	6.34%	-525.62%	-37.44%
EBIT Growth	0.00%	-384.37%	6.36%	-525.60%	-37.35%
NOPAT Growth	0.00%	-409.00%	89.46%	-5,043.86%	3.65%
Net Income Growth	0.00%	-360.89%	30.07%	-681.73%	-36.54%
EPS Growth	0.00%	-80.82%	13.11%	-80.67%	-19.07%
Operating Cash Flow Growth	0.00%	-291.24%	137.45%	-1,424.13%	-12.28%
Free Cash Flow Firm Growth	0.00%	0.00%	-176.58%	51.69%	-269.23%
Invested Capital Growth	0.00%	0.00%	1,464.64%	-205.66%	-47.32%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	35.63%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-20.91%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-20.81%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	4.26%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-21.46%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-13.78%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-2.86%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-74.82%
Profitability Metrics	-	-	-	-	-
Gross Margin	0.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	0.00%	-315,217.31%	-29.28%	-1,335.30%	-567.55%
Operating Margin	0.00%	-331,406.51%	-3.46%	-1,298.56%	-386.91%
EBIT Margin	0.00%	-315,372.86%	-29.29%	-1,335.65%	-567.30%
Profit (Net Income) Margin	0.00%	-317,772.91%	-22.04%	-1,255.76%	-530.25%
Tax Burden Percent	100.00%	100.00%	100.00%	100.02%	100.00%
Interest Burden Percent	105.89%	100.76%	75.24%	94.00%	93.47%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-10.91%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-3.29%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	3.03%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-57.44%	-7.88%	-43.87%	-46.20%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-112.38%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	-47.48%	-9.45%	-41.10%	-42.66%
Return on Assets (ROA)	0.00%	-47.84%	-7.11%	-38.64%	-39.88%
Return on Common Equity (ROCE)	0.00%	-57.44%	-7.88%	-43.87%	-46.20%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-57.44%	-4.37%	-61.35%	-31.89%
Net Operating Profit after Tax (NOPAT)	-4.64	-24	-2.49	-128	-123
NOPAT Margin	0.00%	-231,984.56%	-2.42%	-908.99%	-270.84%
Net Nonoperating Expense Percent (NNEP)	0.00%	-29.15%	-7.62%	-12.07%	-20.12%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-0.48%	-44.41%	-16.29%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	53,367.71%	19.00%	267.09%	154.61%
R&D to Revenue	0.00%	278,138.80%	84.47%	1,131.47%	332.30%
Operating Expenses to Revenue	0.00%	331,506.51%	103.46%	1,398.56%	486.91%
Earnings before Interest and Taxes (EBIT)	-6.63	-32	-30	-188	-258
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-6.63	-32	-30	-188	-259
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	3.16	3.13
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	3.16	3.14
Price to Revenue (P/Rev)	0.00	0.00	0.00	64.66	52.11
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	40.49	33.80
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-1.06	-0.92	-1.00	-1.12
Leverage Ratio	0.00	1.20	1.11	1.14	1.16
Compound Leverage Factor	0.00	1.21	0.83	1.07	1.08
Debt to Total Capital	0.00%	0.22%	0.01%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.22%	0.01%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	99.78%	99.99%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	1.87	15.60	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	-0.01	-0.02	0.00	0.00
Net Debt to NOPAT	0.00	2.54	188.39	0.00	0.00
Long-Term Debt to NOPAT	0.00	-0.01	-0.02	0.00	0.00
Altman Z-Score	0.00	0.00	0.00	7.31	12.51
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-
Current Ratio	0.00	5.96	12.64	6.95	8.08
Quick Ratio	0.00	5.96	12.64	6.82	7.80
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-20	-55	-27	-99
Operating Cash Flow to CapEx	0.00%	-125,820.00%	4,825.79%	-588,408.33%	-23,595.83%
Free Cash Flow to Firm to Interest Expense	0.00	-81.89	-192.93	0.00	0.00
Operating Cash Flow to Interest Expense	-17.32	-116.50	37.16	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-17.32	-116.59	36.39	0.00	0.00
Efficiency Ratios	-	-	-	-	-
Asset Turnover	0.00	0.00	0.32	0.03	0.08
Accounts Receivable Turnover	0.00	0.00	12.21	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.05	556.47	140.86	316.41
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	234,496.84	29.90	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	234,496.84	29.90	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	0.00	-3.61	49	-52	-77
Invested Capital Turnover	0.00	-0.01	4.50	-10.11	-0.71
Increase / (Decrease) in Invested Capital	0.00	-3.61	53	-101	-25
Enterprise Value (EV)	0.00	0.00	0.00	571	1,540
Market Capitalization	0.00	0.00	0.00	911	2,374
Book Value per Share	$0.00	$0.00	$6.36	$3.54	$8.20
Tangible Book Value per Share	$0.00	$0.00	$5.26	$3.53	$8.19
Total Capital	0.00	56	518	288	758
Total Debt	0.00	0.13	0.06	0.00	0.00
Total Long-Term Debt	0.00	0.13	0.06	0.00	0.00
Net Debt	0.00	-60	-469	-340	-834
Capital Expenditures (CapEx)	0.00	0.02	0.22	0.02	0.67
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-4.64	-28	-44	-78
Debt-free Net Working Capital (DFNWC)	0.00	55	441	297	756
Net Working Capital (NWC)	0.00	55	441	297	756
Net Nonoperating Expense (NNE)	2.38	8.74	20	49	118
Net Nonoperating Obligations (NNO)	0.00	-60	-469	-340	-834
Total Depreciation and Amortization (D&A)	0.00	0.02	0.01	0.05	-0.11
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-45,534.23%	-26.93%	-309.13%	-170.52%
Debt-free Net Working Capital to Revenue	0.00%	544,388.46%	429.90%	2,107.13%	1,660.33%
Net Working Capital to Revenue	0.00%	544,388.46%	429.90%	2,107.13%	1,660.33%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	($2.15)	($2.56)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	0.00	89.27M	109.82M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	($2.15)	($2.56)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	0.00	89.27M	109.82M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	0.00	89.27M	109.82M
Normalized Net Operating Profit after Tax (NOPAT)	-4.64	-24	-2.49	-128	-123
Normalized NOPAT Margin	0.00%	-231,984.56%	-2.42%	-908.99%	-270.84%
Pre Tax Income Margin	0.00%	-317,772.91%	-22.04%	-1,255.57%	-530.25%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	-15.78	-131.40	-104.82	0.00	0.00
NOPAT to Interest Expense	-11.05	-96.66	-8.68	0.00	0.00
EBIT Less CapEx to Interest Expense	-15.78	-131.50	-105.59	0.00	0.00
NOPAT Less CapEx to Interest Expense	-11.05	-96.75	-9.45	0.00	0.00
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	-0.22%

This table displays calculated financial ratios and metrics derived from NewAmsterdam Pharma's official financial filings.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	-83.76%	32.73%	889.83%	1,490.54%
EBITDA Growth	0.00%	0.00%	0.00%	0.00%	-125.45%	-2.25%	58.02%	-85.35%
EBIT Growth	0.00%	0.00%	0.00%	0.00%	-125.44%	-2.27%	57.98%	-85.40%
NOPAT Growth	0.00%	0.00%	0.00%	0.00%	-39.22%	-23.76%	49.55%	15.36%
Net Income Growth	0.00%	0.00%	0.00%	0.00%	-123.16%	-1.87%	64.68%	-86.24%
EPS Growth	0.00%	0.00%	0.00%	0.00%	-107.84%	12.77%	68.42%	-51.67%
Operating Cash Flow Growth	0.00%	0.00%	0.00%	0.00%	-71.36%	-84.20%	73.39%	-13.32%
Free Cash Flow Firm Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-47.32%
Revenue Q/Q Growth	0.00%	-80.10%	71.29%	-72.70%	0.00%	62.67%	1,177.36%	-56.13%
EBITDA Q/Q Growth	0.00%	0.14%	-16.99%	-3.88%	0.00%	54.71%	51.97%	-358.68%
EBIT Q/Q Growth	0.00%	0.13%	-16.99%	-3.87%	0.00%	54.70%	51.93%	-358.31%
NOPAT Q/Q Growth	0.00%	-6.60%	-16.66%	-3.06%	0.00%	5.24%	52.44%	-72.90%
Net Income Q/Q Growth	0.00%	8.87%	-23.09%	-5.01%	0.00%	58.40%	57.32%	-453.72%
EPS Q/Q Growth	0.00%	7.84%	-21.28%	-5.26%	0.00%	61.32%	56.10%	-405.56%
Operating Cash Flow Q/Q Growth	0.00%	8.03%	-60.30%	29.59%	0.00%	1.14%	76.84%	-199.80%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	-78.80%	307.72%	-121.34%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	37.60%	-1.38%	-74.82%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-497.76%	-2,498.02%	-1,706.15%	-6,491.03%	-6,911.85%	-1,924.44%	-72.35%	-756.43%
Operating Margin	-461.85%	-2,474.20%	-1,685.07%	-6,360.40%	-3,960.17%	-2,306.93%	-85.89%	-338.47%
EBIT Margin	-497.87%	-2,498.78%	-1,706.63%	-6,492.65%	-6,912.92%	-1,925.27%	-72.45%	-756.83%
Profit (Net Income) Margin	-486.94%	-2,230.11%	-1,602.62%	-6,163.76%	-6,692.86%	-1,711.58%	-57.18%	-721.71%
Tax Burden Percent	100.00%	100.00%	100.00%	100.05%	100.00%	100.00%	99.99%	100.00%
Interest Burden Percent	97.81%	89.25%	93.91%	94.88%	96.82%	88.90%	78.93%	95.36%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	0.00%	0.00%	-43.87%	-55.53%	-59.21%	-52.50%	-46.20%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	-199.79%	-97.11%	-32.00%	-5.54%	-56.92%
Return on Assets (ROA)	0.00%	0.00%	0.00%	-189.67%	-94.02%	-28.45%	-4.37%	-54.28%
Return on Common Equity (ROCE)	0.00%	0.00%	0.00%	-43.87%	-55.53%	-59.21%	-52.50%	-46.20%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	0.00%	0.00%	-55.53%	-59.21%	-52.50%	0.00%
Net Operating Profit after Tax (NOPAT)	-28	-30	-35	-36	-39	-37	-18	-30
NOPAT Margin	-323.29%	-1,731.94%	-1,179.55%	-4,452.28%	-2,772.12%	-1,614.85%	-60.12%	-236.93%
Net Nonoperating Expense Percent (NNEP)	0.00%	0.00%	0.00%	-4.04%	-22.83%	-1.02%	0.40%	-10.54%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-12.40%	-	-	-	-3.99%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	93.43%	574.14%	310.37%	1,318.18%	1,031.62%	722.90%	63.25%	165.25%
R&D to Revenue	468.42%	2,000.06%	1,474.70%	5,142.22%	3,028.55%	1,684.03%	122.64%	273.21%
Operating Expenses to Revenue	561.85%	2,574.20%	1,785.07%	6,460.40%	4,060.17%	2,406.93%	185.89%	438.47%
Earnings before Interest and Taxes (EBIT)	-43	-43	-50	-52	-97	-44	-21	-97
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-43	-43	-50	-52	-97	-44	-21	-97
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	3.16	4.68	4.46	3.94	3.13
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	3.16	4.69	4.47	3.95	3.14
Price to Revenue (P/Rev)	0.00	0.00	0.00	64.66	281.10	232.82	44.48	52.11
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	40.49	210.98	174.80	31.90	33.80
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	0.00	0.00	-1.18	-1.17	-1.11	-1.12	-1.12
Leverage Ratio	0.00	0.00	0.00	1.14	1.19	1.15	1.16	1.16
Compound Leverage Factor	0.00	0.00	0.00	1.08	1.15	1.03	0.92	1.10
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	0.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	0.00	0.00	8.60	14.33	16.86	14.38	13.13
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	0.00	0.00	0.00	6.95	8.17	9.83	10.61	8.08
Quick Ratio	0.00	0.00	0.00	6.82	8.06	9.51	10.25	7.80
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	0.00	0.00	0.00	31	6.47	26	-5.63
Operating Cash Flow to CapEx	-455,185.71%	-586,100.00%	-521,955.56%	-1,102,466.67%	-14,182.34%	-25,827.27%	-16,669.33%	-1,249,366.67%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.03	0.01	0.02	0.08	0.08
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	140.86	67.94	31.73	145.43	316.41
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	0.00	0.00	0.00	-52	-69	-43	-44	-77
Invested Capital Turnover	0.00	0.00	0.00	-0.27	-0.20	-0.34	-1.53	-0.71
Increase / (Decrease) in Invested Capital	0.00	0.00	0.00	0.00	-69	-43	-44	-25
Enterprise Value (EV)	0.00	0.00	0.00	571	1,448	1,298	1,072	1,540
Market Capitalization	1,081	970	754	911	1,929	1,728	1,494	2,374
Book Value per Share	$0.00	$0.00	$0.00	$3.54	$4.58	$4.31	$4.21	$8.20
Tangible Book Value per Share	$0.00	$0.00	$0.00	$3.53	$4.57	$4.30	$4.20	$8.19
Total Capital	0.00	0.00	0.00	288	412	387	379	758
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	0.00	0.00	-340	-481	-431	-423	-834
Capital Expenditures (CapEx)	0.01	0.01	0.01	0.00	0.39	0.21	0.08	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	0.00	0.00	-44	-53	-31	-26	-78
Debt-free Net Working Capital (DFNWC)	0.00	0.00	0.00	297	428	400	397	756
Net Working Capital (NWC)	0.00	0.00	0.00	297	428	400	397	756
Net Nonoperating Expense (NNE)	14	8.55	12	14	55	2.20	-0.86	62
Net Nonoperating Obligations (NNO)	0.00	0.00	0.00	-340	-481	-431	-423	-834
Total Depreciation and Amortization (D&A)	0.01	0.01	0.01	0.01	0.02	0.02	0.03	0.05
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	-309.13%	-773.11%	-413.03%	-77.72%	-170.52%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	2,107.13%	6,238.65%	5,388.54%	1,180.62%	1,660.33%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	2,107.13%	6,238.65%	5,388.54%	1,180.62%	1,660.33%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	($0.60)	($1.06)	($0.41)	($0.18)	($0.91)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	0.00	89.27M	89.98M	90.02M	92.39M	109.82M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	($0.60)	($1.06)	($0.41)	($0.18)	($0.91)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	0.00	89.27M	89.98M	90.02M	92.39M	109.82M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	0.00	89.27M	89.98M	90.02M	92.39M	109.82M
Normalized Net Operating Profit after Tax (NOPAT)	-28	-30	-35	-36	-39	-37	-18	-30
Normalized NOPAT Margin	-323.29%	-1,731.94%	-1,179.55%	-4,452.28%	-2,772.12%	-1,614.85%	-60.12%	-236.93%
Pre Tax Income Margin	-486.94%	-2,230.11%	-1,602.62%	-6,160.40%	-6,692.86%	-1,711.58%	-57.19%	-721.71%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.22%

Frequently Asked Questions About NewAmsterdam Pharma's Financials

When does NewAmsterdam Pharma's fiscal year end?

According to the most recent income statement we have on file, NewAmsterdam Pharma's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has NewAmsterdam Pharma's net income changed over the last 4 years?

NewAmsterdam Pharma's net income appears to be on an upward trend, with a most recent value of -$241.60 million in 2024, rising from -$7.02 million in 2020. The previous period was -$176.94 million in 2023.

What is NewAmsterdam Pharma's operating income?

NewAmsterdam Pharma's total operating income in 2024 was -$176.29 million, based on the following breakdown:

Total Gross Profit: $45.56 million
Total Operating Expenses: $221.85 million

How has NewAmsterdam Pharma revenue changed over the last 4 years?

Over the last 4 years, NewAmsterdam Pharma's total revenue changed from $0.00 in 2020 to $45.56 million in 2024, a change of 4,556,300,000.0%.

How much debt does NewAmsterdam Pharma have?

NewAmsterdam Pharma's total liabilities were at $107.12 million at the end of 2024, a 82.5% increase from 2023, and a 847.3% increase since 2021.

How much cash does NewAmsterdam Pharma have?

In the past 3 years, NewAmsterdam Pharma's cash and equivalents has ranged from $60.09 million in 2021 to $771.74 million in 2024, and is currently $771.74 million as of their latest financial filing in 2024.

How has NewAmsterdam Pharma's book value per share changed over the last 4 years?

Over the last 4 years, NewAmsterdam Pharma's book value per share changed from 0.00 in 2020 to 8.20 in 2024, a change of 819.9%.

Remove Ads

Related Companies

This page (NASDAQ:NAMS) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NewAmsterdam Pharma (NAMS) Financials

Frequently Asked Questions About NewAmsterdam Pharma's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NewAmsterdam Pharma (NAMS) Financials

Annual Income Statements for NewAmsterdam Pharma

Quarterly Income Statements for NewAmsterdam Pharma

Annual Cash Flow Statements for NewAmsterdam Pharma

Quarterly Cash Flow Statements for NewAmsterdam Pharma

Annual Balance Sheets for NewAmsterdam Pharma

Quarterly Balance Sheets for NewAmsterdam Pharma

Annual Metrics and Ratios for NewAmsterdam Pharma

Quarterly Metrics and Ratios for NewAmsterdam Pharma

Frequently Asked Questions About NewAmsterdam Pharma's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools